Ulrika Yngve
Forskare vid Institutionen för läkemedelskemi; Preparativ läkemedelskemi
- Telefon:
- 018-471 41 24
- E-post:
- ulrika.yngve@scilifelab.uu.se
- Besöksadress:
- Uppsala Biomedicinska Centrum, BMC, Husarg. 3
- Postadress:
- Box 574
751 23 UPPSALA
Mer information visas för dig som medarbetare om du loggar in.
Kort presentation
Head of Facility för Medicinal Chemistry, Lead Identification, Drug Discovery and Development Platform, Science for Life Laboratory. Information om plattformen finns på https://www.scilifelab.se/platforms/ddd.
Jag är läkemedelskemist med 12 års erfarenhet av industriell läkemedelsforskning vid AstraZeneca i Södertälje. I vårt arbete vid plattformen samarbetar vi med akademiska forskare för att leverera högkvalitativa föreningar och data i projekt med syfte att ta fram nya läkemedel.
Publikationer
Urval av publikationer
- Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability (2020)
- A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage (2018)
- Brain mGluR5 in mice with amyloid beta pathology studied with in vivo [(11)C]ABP688 PET imaging and ex vivo immunoblotting (2017)
- Triazolopyrimidinones as gamma-secretase modulators (2013)
- Imidazopyridine-based inhibitors of glycogen synthase kinase 3 (2012)
Senaste publikationer
- Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability (2020)
- A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage (2018)
- Automated GMP-production of α-[11 C]methyl-L-tryptophan using a tracer production system (TPS) (2018)
- Brain mGluR5 in mice with amyloid beta pathology studied with in vivo [(11)C]ABP688 PET imaging and ex vivo immunoblotting (2017)
- Tracing BACE (2015)
Alla publikationer
Artiklar
- Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability (2020)
- A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage (2018)
- Automated GMP-production of α-[11 C]methyl-L-tryptophan using a tracer production system (TPS) (2018)
- Brain mGluR5 in mice with amyloid beta pathology studied with in vivo [(11)C]ABP688 PET imaging and ex vivo immunoblotting (2017)
- Tracing BACE (2015)
- Triazolopyrimidinones as gamma-secretase modulators (2013)
- 3-Oxoisoindoline-1-carboxamides (2012)
- Imidazopyridine-based inhibitors of glycogen synthase kinase 3 (2012)
- Microwave accelerated 68Ga-labelling of oligonucleotides (2004)
- Hybridisation of [Br-76]-labelled antisense oligonucleotides to Chromogranin A mRNA verified by RT-PCR (2004)
- Labelling of octreotide using Br-76-prosthetic groups (2001)
- Determination of specific radioactivity for Br-76-labeled compounds measuring the ratio between Br-76 and Br-79 using packed capillary liquid chromatography mass spectrometry (2000)
- Distribution of Br-76-labeled antisense oligonucleotides of different length determined ex vivo in rats (2000)
- Compounds labelled with short-lived beta(+)-emitting radionuclides and some applications in life sciences. The importance of time as a parameter (1999)
- Synthesis of N-Succinimidyl 4-[76Br]Bromobenzoate and its Use in Conjugation Labelling of Macromolecules (1999)
Konferenser
- Tritium labeling of a class of spirooxazaindolamines possessing analgesic properties. (2004)
- Synthesis of N-succinimidyl-4-[76Br]bromobenzoate and its use in labeling of amino-containing macromolecules. (1998)
Patent
- Preparation of pyrimidinylamine compounds as gamma secretase modulators useful for treatment of Aβ-related diseases. (2014)
- Preparation of aminotriazole compounds as gamma secretase modulators useful for treatment of Aβ-related diseases. (2014)
- Preparation of azetidinotriazole compounds as gamma secretase modulators useful for treatment of Aβ-related diseases. (2014)
- Preparation of 1-(4-(5-amino-6-(oxazolo[4,5-c]pyridin-2-yl)pyrazin-2-yl)benzoyl)piperazine derivatives as glycogen synthase kinase 3 inhibitors. (2011)
- Preparation of arylimidazopyridine derivatives for use as GSK3 modulators. (2008)
- Preparation of imidazopyridinecarboxamide derivatives for use as GSK3 modulators. (2008)
- Preparation of imidazolyl-pyrimidine derivatives as GSK3 inhibitors. (2008)
- Preparation of piperazinyl quinazolines as 5-HT6 modulators. (2007)
- Preparation of piperazinyl quinazolines as 5-HT6 modulators. (2007)
- Benzoic acid derivatives as glycine receptor inhibitors, their preparation, pharmaceutical compositions, and use in therapy. (2006)
- Preparation of five-membered heterocyclic compounds as mGluR5 receptor antagonists. (2004)
